Before life sciences companies reported first-quarter earnings, a jump in sales might have been expected as companies and patients stocked up ahead of tariffs. But in the event, this was less pronounc
A slower-than-usual year for medtech M&A in 2023 was reflected in relatively few company exits from the Top 100 annual listing of publicly traded device, diagnostics and healthtech companies by re
A slower-than-usual year for medtech M&A in 2023 was reflected in relatively few company exits from the Top 100 annual listing of publicly traded device, diagnostics and healthtech companies by re
Becton, Dickinson and Company chair, CEO and president Tom Polen was clear about the medtech industry’s contribution to the ongoing transformation of health care. Speaking to delegates on the opening